NSD2 as a Promising Target in Hematological Disorders.

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• Epigenetic modifications, such as Histone 3 Lysine 36 dimethylation (H3K36me2), are crucial in cancer development.
• H3K36me2, primarily mediated by Nuclear SET Domain (NSD) proteins, plays a significant role in genome regulation.
• NSD2 is vital for hematopoietic development and frequently altered in hematological malignancies.

Purpose of the Study:

• To discuss the role of NSD2 in cancer, especially hematological malignancies.
• To review recent findings on NSD2 as an anticancer target.
• To highlight the development of novel compounds targeting oncogenic NSD2.

Main Methods:

• Literature review of studies on NSD2 function in cancer.
• Analysis of recent research on NSD2 alterations in hematological malignancies.
• Compilation of data on emerging therapeutic compounds targeting NSD2.

Main Results:

• NSD2 alterations are implicated in the development and maintenance of various cancers.
• NSD2 plays a critical role in normal hematopoietic development.
• Specific compounds targeting oncogenic NSD2 are under active investigation.

Conclusions:

• NSD2 is a relevant target for anticancer therapies, particularly in hematological cancers.
• Targeting NSD2 offers a promising strategy for novel cancer treatments.
• Further research into NSD2-targeting compounds is warranted.